493 related articles for article (PubMed ID: 26931561)
1. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Homet Moreno B; Garralda Cabanas E; Hitt R
Clin Transl Oncol; 2010 Jul; 12(7):468-72. PubMed ID: 20615823
[TBL] [Abstract][Full Text] [Related]
3. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD
Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
[TBL] [Abstract][Full Text] [Related]
4. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas.
Shor AC; Agresta SV; D'Amato GZ; Sondak VK
Cancer Control; 2008 Jan; 15(1):47-54. PubMed ID: 18094660
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib as an emerging treatment for sarcoma.
Schöffski P; Blay JY; Ray-Coquard I
Curr Opin Oncol; 2020 Jul; 32(4):321-331. PubMed ID: 32541320
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
[TBL] [Abstract][Full Text] [Related]
8. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted therapies in the treatment of soft-tissue sarcomas.
Chao J; Chow WA; Somlo G
Expert Rev Anticancer Ther; 2010 Aug; 10(8):1303-11. PubMed ID: 20735315
[TBL] [Abstract][Full Text] [Related]
11. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of soft tissue sarcomas based on the histological subtype].
Pápai Z
Magy Onkol; 2014 Mar; 58(1):53-8. PubMed ID: 24712007
[TBL] [Abstract][Full Text] [Related]
13. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
15. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
Napolitano A; Ostler AE; Jones RL; Huang PH
Cells; 2021 Jun; 10(6):. PubMed ID: 34204560
[TBL] [Abstract][Full Text] [Related]
17. [Targeted therapy of sarcomas].
Cassier PA; Dufresne A; El Sayadi H; Pissaloux D; Alberti L; Decouvelaere AV; Ranchere D; Ray-Coquard I; Blay JY
Bull Cancer; 2008 Oct; 95(10):963-74. PubMed ID: 19004727
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib for the Treatment of Sarcoma.
Blay JY; Duffaud F; George S; Maki RG; Penel N
Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for cancer: the gastrointestinal stromal tumor model.
Balachandran VP; Dematteo RP
Surg Oncol Clin N Am; 2013 Oct; 22(4):805-21. PubMed ID: 24012400
[TBL] [Abstract][Full Text] [Related]
20. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
